{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-069825","form_type":"8-K","ticker":"CGON","cik":"0001991792","company_name":"CG Oncology, Inc.","filed_at":"2025-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.649848+00:00","generated_at":"2026-05-21T18:56:37.502054+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"confidence":"high","headline":"CG Oncology Q1 net loss $34.5M; BLA submission on track for H2 2025","bullets":["Net loss of $34.5M ($0.45/share) vs $16.9M ($0.36) a year ago; R&D spend rose to $27.5M.","Cash $688.4M as of March 31, 2025; expected to fund operations into first half of 2028.","BOND-003 Cohort C: 75.5% CR at any time; 24-month CR rate 42.3% by K-M; 97.3% progression-free at 24 months.","Cohort P: 90.5% high-grade recurrence-free survival at 3 and 9 months in BCG-unresponsive Ta/T1 disease.","Anticipates starting BLA submission for cretostimogene in HR BCG-unresponsive NMIBC in H2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-069825","json":"https://secwatch.observer/filing/0000950170-25-069825.json","markdown":"https://secwatch.observer/filing/0000950170-25-069825.md","text":"https://secwatch.observer/filing/0000950170-25-069825.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1991792/000095017025069825/0000950170-25-069825-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1991792/000095017025069825/ck0001991792-20250513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T18:56:37.502054+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}